ライフサイエンスコーパス: veltuzumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 at are fused to the humanized anti-CD20 mAb, veltuzumab.

2 t CD22 (epratuzumab), CD74 (milatuzumab), or veltuzumab.

3 g) was initiated 1 wk after PT-RAIT or (90)Y-veltuzumab.

4 ven low intravenous or subcutaneous doses of veltuzumab.

5 tribution data indicated that when unlabeled veltuzumab (1.0 or 0.25 mg) was administered in advance

6 or uptake was significantly reduced ((111)In-veltuzumab, 47% and 25%, respectively; (111)In-hapten-pe

7 new drug protocol was approved to administer veltuzumab, a second-generation humanized anti-CD20 anti

8 appa]), 20-22, a bispecific HexAb comprising veltuzumab and 4 Fabs of epratuzumab (humanized anti-CD2

9 blood more potently than the combination of veltuzumab and a nontargeting, irrelevant, mAb-IFN-alpha

10 the differentiation of the off-rate between veltuzumab and rituximab is related to the single amino

11 were not diminished significantly for (90)Y-veltuzumab, and in the case of PT-RAIT responses were im

12 ecific HexAbs [IgG-(Fab)(4) constructed from veltuzumab (anti-CD20 IgG) and milatuzumab (anti-CD74 Ig

13 ficacy in tumor-bearing mice comparable with veltuzumab at equivalent doses.

14 ependent cellular cytotoxicity compared with veltuzumab but lacks complement-dependent cytotoxicity.

15 nomolgus monkeys disclosed that low doses of veltuzumab control tumor growth or deplete circulating o

16 adiolabeled, humanized, (90)Y-anti-CD20 IgG (veltuzumab) could be improved by combining these treatme

17 Clinical trials of subcutaneous veltuzumab for PV are warranted.

18 Relapse and response to veltuzumab generally correlated with desmoglein 3 enzyme

19 ned the effect that predosing with unlabeled veltuzumab had on radioimmunotherapy and PT-RAIT targeti

20 When compared with rituximab, veltuzumab has significantly reduced off-rates in 3 huma

21 0, a monospecific HexAb comprising 6 Fabs of veltuzumab (humanized anti-CD20 immunoglobulin G1kappa [

22 (bsAbs) were recombinantly constructed from veltuzumab (humanized anti-CD20) and epratuzumab (humani

23 LA-DR; IMMU-114) site-specifically linked to veltuzumab (humanized anti-CD20).

24 Only combinations with veltuzumab improved therapeutic responses, most signific

25 Veltuzumab is a humanized anti-CD20 monoclonal antibody

26 Serum veltuzumab levels were 22 and 29 mug/mL 2 weeks after th

27 Subcutaneous veltuzumab may be a safe, effective, and more economical

28 administered in advance of the radiolabeled veltuzumab or bispecific antibody injection, tumor uptak

29 superior therapeutic efficacy compared with veltuzumab or nontargeting mAb-IFN-alpha in 3 human lymp

30 e HexAbs from those incurred by crosslinking veltuzumab or rituximab with a secondary antibody.

31 However, higher amounts of predosed veltuzumab reduced the effects of PT-RAIT.

32 apeutic responses, most significantly when a veltuzumab regimen (weekly, 1.0 mg followed by 3 x 0.5 m

33 etra-hA20, comprising three and four Fabs of veltuzumab, respectively.

34 in CDR3-V(H) of rituximab is responsible for veltuzumab's lower off-rate and apparent improved potenc

35 A second cycle of subcutaneous veltuzumab, using the same dosage regimen, again induced

36 2 bispecific antibodies (bsAbs) derived from veltuzumab (v-mab) and epratuzumab (e-mab).

37 Veltuzumab was administered as two 320-mg (188mg/m2) sub

38 Low- and high-dose veltuzumab were significantly more effective in vivo tha

39 c HexAb comprising epratuzumab and 4 Fabs of veltuzumab, were previously shown to inhibit pro-liferat

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。